0.4470SEK+3.83%Mkt Cap: 69.27M SEKP/E: —Last update: 2026-06-01
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment o…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap69.27M SEK
Enterprise Value34.33M SEK
Revenue (TTM)25.66M SEK
Gross Profit26.55M SEK
Net Income (TTM)-26.27M SEK
Revenue/Share0.2730 SEK
Last Price0.4470 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees7
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.72
PEG—
EV/EBITDA—
EV/Revenue1.34
P/S2.60
P/B0.37
EPS (TTM)-0.20
EPS (Forward)-0.60
52W Range
0.38603% of range2.280
52W High2.280 SEK
52W Low0.3860 SEK
Profitability
Gross Margin100.00%
Oper. Margin-99.01%
EBITDA Margin0.00%
Profit Margin-103.58%
ROE-21.54%
ROA-18.31%
Growth
Revenue Growth-18.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.03M SEK
CapEx (TTM)26.55M SEK
FCF Margin-153.96%
FCF Yield-57.03%
Net Debt-10.58M SEK
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.01
Current Ratio1.37
Quick Ratio1.33
Book Value/Sh1.169 SEK
Cash/Share0.1090 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)2.300 SEK
Target Range2.000 SEK – 2.600 SEK
# Analysts2
Ownership
Shares Out.154.96M
Float83.43M
Insiders17.77%
Institutions8.62%
Technical
SMA 500.5175 (-13.6%)
SMA 2000.9945 (-55.1%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)1.12M
Avg Vol (10d)1.40M
Technical Indicators
RSI (14)41.2
MACD-0.0197
MACD Signal-0.0242
MACD Hist.+0.0045
BB Upper0.5056 SEK
BB Middle0.4447 SEK
BB Lower0.3838 SEK
BB Width27.40%
ATR (14)0.0477 SEK
Vol Ratio (20d)0.83x